Top Markets
Coin of the day
Regulus Therapeutics Inc. Regulus Therapeutics Inc.

Regulus Therapeutics Inc.

RGLS
Pozycja w akcjach #17600
Regulus Therapeutics Inc., a biopharmaceutical firm in its clinical development... Regulus Therapeutics Inc., a biopharmaceutical firm in its clinical development phase, is dedicated to uncovering and advancing novel medications. Based in San Diego, California, the company's core focus is on modulating microRNAs to combat a variety of diseases across the United States. Its current pipeline highlights RG-012, an anti-miR compound engineered to inhibit miR-21, which is currently in a Phase II clinical study for Alport syndrome, a severe renal condition. Another significant candidate, RGLS8429, an anti-miR agent targeting miR-17, is being evaluated in a Phase 1b clinical trial for autosomal dominant polycystic kidney disease. Beyond these clinical programs, Regulus is also cultivating an extensive preclinical portfolio, emphasizing drug candidates with precise, organ-selective delivery strategies. The company was established in 2007.
Cena akcji
$8.16
Ostatnia synchronizacja: 2025-06-26
Kapitalizacja rynkowa
$234.57M
Zmiana (1 dzień)
0.00%
Zmiana (1 rok)
0.00%
Kraj
US
Handel Regulus Therapeutics Inc. (RGLS)

Kategoria

Zyski dla Regulus Therapeutics Inc. (RGLS)
Zyski w Mar 2025 TTM: $-47.52M
Według najnowszych raportów finansowych Regulus Therapeutics Inc., obecny zysk firmy wynosi $-47.52M. W roku 2023 firma osiągnęła zysk w wysokości $-30.04M, spadek w porównaniu do zysku z roku 2022, który wynosił $-28.32M. Wyświetlany zysk to zysk przed odsetkami i podatkami, czyli EBIT.
Historia zysków firmy Regulus Therapeutics Inc. od 2010 do 2026
Zyski na koniec każdego roku
Rok Zyski Zmień
2026 (TTM) $-47.52M 2.51%
2024 $-46.36M 54.34%
2023 $-30.04M 6.05%
2022 $-28.32M 1.85%
2021 $-27.81M 76.78%
2020 $-15.73M -15.39%
2019 $-18.59M -61.78%
2018 $-48.65M -32.53%
2017 $-72.10M -11.90%
2016 $-81.84M 46.76%
2015 $-55.77M -1.61%
2014 $-56.68M 203.24%
2013 $-18.69M 7.31%
2012 $-17.42M 135.51%
2011 $-7.40M -52.56%
2010 $-15.59M 0.00%
Zyski podobnych firm lub konkurentów
Firma Zyski Różnica w zyskach Kraj
$5.27B -11,199.91%
US
$1.95B -4,204.73%
NL
$-3.09B 6,395.94%
US
$-4.02B 8,351.24%
AU
- -
CH